BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33275608)

  • 1. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.
    Moreno S; Calvo-Pinilla E; Devignot S; Weber F; Ortego J; Brun A
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008942. PubMed ID: 33275608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.
    Smith DR; Johnston SC; Piper A; Botto M; Donnelly G; Shamblin J; Albariño CG; Hensley LE; Schmaljohn C; Nichol ST; Bird BH
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006474. PubMed ID: 29742102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
    Utrilla-Trigo S; Jiménez-Cabello L; Calvo-Pinilla E; Marín-López A; Lorenzo G; Sánchez-Cordón P; Moreno S; Benavides J; Gilbert S; Nogales A; Ortego J
    J Virol; 2022 Feb; 96(3):e0161421. PubMed ID: 34787454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
    Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T
    Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant bluetongue virus with hemagglutinin epitopes in VP2 has potential as a labeled vaccine.
    Guo Y; Huang L; Bi K; Xu Q; Bu Z; Wang F; Sun E
    Vet Microbiol; 2020 Sep; 248():108825. PubMed ID: 32891953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.
    Gowen BB; Bailey KW; Scharton D; Vest Z; Westover JB; Skirpstunas R; Ikegami T
    Antiviral Res; 2013 May; 98(2):135-43. PubMed ID: 23523764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.
    Wichgers Schreur PJ; Kant J; van Keulen L; Moormann RJ; Kortekaas J
    Vaccine; 2015 Mar; 33(12):1459-64. PubMed ID: 25665959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.